Abstract
Despite the progress in the treatment of adult acute myeloid leukemia (AML), most of the patients achieving complete remission (CR) with induction chemotherapy will relapse within 2 years. Therefore, there is an urgent need for new developments in the treatment of adult AML. The application of new chemotherapeutic drugs may be one way to achieve success. Because anthracyclines are highly effective in the treatment of AML, it may be possible that anthracycline analogues will increase the therapeutic results.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Bernardi L, Giardino P, et al. (1976) Synthesis and antitumor activity of 4demethoxydaunorubicin, 4-demethoxy-7, 9diepidaunorubicin and their beta anomers. Cancer Treat Rep 60: 829–834
Casazza AM, Pratesi G, Giuliani F, et al. (1980) Antileukemic activity of 4-demethoxydaunorubicin in mice. Tumori 66: 549–564
Casazza AM, Bertazzolli C, Pratesi G, et al. (1979) Antileukemic activity and cardiotoxicity of 4-demethoxydaunorubicin. Proc Am Assoc Cancer Res 20: 16
Di Marco A, Casazza AM, Pratesi G (1977) Antitumor activity of 4-demethoxydaunorubicin administered orally. Cancer Treat Rep 61: 893–894
Lu K, Savaraj M, Kavanagh J, et al. (1984) Clinical pharmacology of 4-demethoxydaunorubicin. Proc ASCO 3: 38
Hancock C, Niedzwiecki D, Merke D, et al. (1985) Pharmocokinetics of idarubicin with or without cytarabine in patients with relapsed leukemia. Proc AACR 26: 157
Büchner Th, Urbanitz K, Emmerich B, et al. (1982) Multicenter study on intensified remission induction therapy for acute myeloid leukemia. Leuk Res 6: 827–831
Polli EE, Lambertenghi-Deliliers G, Maiolo AT, et al. (1983) Treatment of adult leukemia with 4-demethoxydaunorubicin. Proc 13th Intern Congr of Chemother, SY 88–12, pt 215, p 51
Carella AM, Santini G, Martinengo M, et al. (1985) Idarubicin (4-demethoxydaunorubicin) alone or in combination with citarabine and etoposide (3 + 3 + 5 protocol) in acute nonlymphoblastic leukemia. Proc 14th Intern Congr of Chemother, WS 4–16, p 40
Carella AM, Santini G, Martinengo M, et al. (1985) 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemia. A pilot study. Cancer 55: 1452–1454
Young DW, Arlin ZA, Daghestani AN, et al. (1983) Phase I and II evaluation of 4-demethoxydaunorubicin in acute leukemia: Proc 13th Intern Congr of Chemother, SY 88–11, p 215, p48
Berman E, Arlin Z, Daghestani A, et al. (1982) Phase I-II study of idarubicin and cytarabine in acute leukemia. Proc Am Assoc Cancer Res 25: 187
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fülle, H.H., Hellriegel, K.P. (1987). 4-Demethoxydaunorubicin (Idarubicin) in Relapsed and Refractory Acute Myeloid Leukemia. In: Büchner, T., Schellong, G., Hiddemann, W., Urbanitz, D., Ritter, J. (eds) Acute Leukemias. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 30. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-71213-5_55
Download citation
DOI: https://doi.org/10.1007/978-3-642-71213-5_55
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-16556-9
Online ISBN: 978-3-642-71213-5
eBook Packages: Springer Book Archive